Pegaptanib Sodium for the Treatment of Proliferative Diabetic Retinopathy and Diabetic Macular Edema

Authors: Giuliari, Gian P.; Guel, David A.; Gonzalez, Victor H.

Source: Current Diabetes Reviews, Volume 5, Number 1, February 2009 , pp. 33-38(6)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $62.88 plus tax (Refund Policy)

Abstract:

Diabetes mellitus is a growing health concern world-wide. Patients with this disease present with a variety of health conditions, including a number of sight-threatening ocular pathologies. Proliferative diabetic retinopathy (PDR) and diabetic macula edema (DME) are common diseases that cause substantial vision impairment in diabetic patients. There has been a strong focus on studying the epidemiology and treatment of these diseases. The recent discovery of vascular endothelial growth factor (VEGF) and its role in the development of proliferative disease, has led to a movement towards treating PDR and DME with anti-angiogenic medications in conjunction with the standard of care.

In this review we present a summary of the origination and progression of PDR and DME. This will be followed by a review of clinical data surrounding new anti-angiogenic treatment modalities.

Keywords: Pegaptanib sodium (Macugen); Proliferative diabetic retinopathy; Diabetic macular edema; Diabetes mellitus

Document Type: Research article

DOI: http://dx.doi.org/10.2174/157339909787314158

Publication date: 2009-02-01

More about this publication?

Current Diabetes Reviews publishes frontier reviews on all the latest advances on diabetes and its related areas e.g. pharmacology, pathogenesis, complications, epidemiology, clinical care, and therapy.

The journal's aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians who are involved in the field of diabetes.